Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective

Figures & data

Figure 1 Illustration of possible ways of patient distribution in the pharmacoeconomic model (Figure 1A: by directly entering the estimated number of patients in each treatment regimen, Figure 1B:  on the basis of the product of the total number of patients and the estimated shares (%) in each treatment regimen).

Table 1 The Results of the Budget Impact Analysis When Using Various Approaches to the Adjustment of “Additional Patients”

	Treatment Cost per Patient, RUB.	Subtraction from the Regimen with the Smallest Share of Distribution	Subtraction from the Regimen with the Largest Share of Distribution	Subtraction from the Regimen with the Least Expensive Regimen
Adjustment approach		I	II	III
The number of patients in each of the regimens after adjustment
BARICITINIB	634,105	−1	2	2
TOCILIZUMAB	590,764	5	5	5
GOLIMUMAB	450,835	24	24	24
ADALIMUMAB	128,495	12	12	12
TOFACITINIB	125,323	8	8	5
SARILUMAB	133,117	11	11	11
Budget impact analysis results, RUB
BARICITINIB		−634,105	1,268,210	1,268,210
TOCILIZUMAB		2,953,820	2,953,820	2,953,820
GOLIMUMAB		10,820,040	10,820,040	10,820,040
ADALIMUMAB		1,541,940	1,541,940	1,541,940
TOFACITINIB		1,002,584	1,002,584	626,615
SARILUMAB		1,464,287	1,464,287	1,464,287
Total		17,148,566	17,698,376	18,674,912
Deviation of results from approach III, %		8,1	5,2

Table 2 Calculations of Distribution Patients by Level of Treatment Costs in Various Schemes

Scheme	Srtucture of Optimal_Risk-Profit, Wadet at Volume	Treatment Cost per Patient, RUB.	0_1	Based at 1 to 2	Volume_Risk-Profit	Subtraction from the Regimen with the Least Expensive Regimen	Patients at Universal Treatment
TOFACITINIB	9,57%	125,323	0	1	0,190,438,085	5	11
ADALIMUMAB	22,91%	128,495	0,0062345	1,00242008	0,189,978,322	12	11
SARILUMAB	20,92%	133,117	0,0153189	1,00594644	0,189,312,351	11	11
GOLIMUMAB	36,79%	450,835	0,6,397,868	1,24,834,955	0,152,551,892	24	9
TOCILIZUMAB	7,06%	590,764	0,9,148,142	1,35,510,845	0,140,533,464	5	9
BARICITINIB	2,76%	634,105	1	1,38,817,549	0,137,185,886	2	8
Total	100%	2,062,639	2,5,761,544	7	100%	59	59

Figure 2 An example of a one-time and uniform entry of patients into the pharmacoeconomic model with a treatment course of 4 months.

Figure 3 An example of a one-time and uniform entry of patients into the pharmacoeconomic model with a treatment course of 1 year.